PTGX - CIK 0001377121
The table below shows Protagonist Therapeutics, Inc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $57.67M | $184.15M | -$70.24M | -$108.14M | -$107.86M | -$72.48M |
| Capital expenditure | $1.59M | $1.35M | $609.00K | $795.00K | $1.10M | $471.00K |
| Investing cash flow | -$49.33M | -$299.48M | -$39.26M | $91.47M | -$15.86M | -$90.97M |
| Dividends paid | - | - | - | - | - |
Protagonist Therapeutics, Inc reported operating cash flow of $57.67M for fiscal year 2025. That is down 68.7% from $184.15M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$29.97M (FY 2016) to $57.67M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $22.86M | $25.85M | $170.48M | $18.84M | $129.92M | $247.63M |